[go: up one dir, main page]

WO2000040232A3 - Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions - Google Patents

Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions Download PDF

Info

Publication number
WO2000040232A3
WO2000040232A3 PCT/US2000/000350 US0000350W WO0040232A3 WO 2000040232 A3 WO2000040232 A3 WO 2000040232A3 US 0000350 W US0000350 W US 0000350W WO 0040232 A3 WO0040232 A3 WO 0040232A3
Authority
WO
WIPO (PCT)
Prior art keywords
kits
compositions
bretylium
preventing
treating cardiovascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/000350
Other languages
French (fr)
Other versions
WO2000040232A2 (en
Inventor
Marvin B Bacaner
Maurice M Kreevoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2358459A priority Critical patent/CA2358459C/en
Priority to DE60018704T priority patent/DE60018704T2/en
Priority to AU26023/00A priority patent/AU781996B2/en
Priority to EP00904237A priority patent/EP1140054B1/en
Priority to MXPA01007024A priority patent/MXPA01007024A/en
Priority to US09/869,940 priority patent/US6482811B1/en
Priority to JP2000591989A priority patent/JP4750278B2/en
Priority to IL14419900A priority patent/IL144199A0/en
Application filed by Individual filed Critical Individual
Priority to AT00904237T priority patent/ATE290857T1/en
Publication of WO2000040232A2 publication Critical patent/WO2000040232A2/en
Publication of WO2000040232A3 publication Critical patent/WO2000040232A3/en
Priority to IL144199A priority patent/IL144199A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention is directed to novel pharmaceutical compositions and kits comprising bretylium as the active ingredient, as well as methods which use such compositions and kits for preventing and/or treating conditions related to the cardiovascular system.
PCT/US2000/000350 1999-01-08 2000-01-06 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions Ceased WO2000040232A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2000591989A JP4750278B2 (en) 1999-01-08 2000-01-06 Novel bretylium compositions and kits and their use in the prevention and treatment of cardiovascular symptoms
AU26023/00A AU781996B2 (en) 1999-01-08 2000-01-06 Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
EP00904237A EP1140054B1 (en) 1999-01-08 2000-01-06 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
MXPA01007024A MXPA01007024A (en) 1999-01-08 2000-01-06 Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions.
US09/869,940 US6482811B1 (en) 1999-01-08 2000-01-06 Bretylium compositions and kits, and their use in preventing and treating cardio-vascular conditions
CA2358459A CA2358459C (en) 1999-01-08 2000-01-06 Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
DE60018704T DE60018704T2 (en) 1999-01-08 2000-01-06 BRETYLIUM-CONTAINING COMPOSITIONS AND KITS AND THEIR USE FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
IL14419900A IL144199A0 (en) 1999-01-08 2000-01-06 Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AT00904237T ATE290857T1 (en) 1999-01-08 2000-01-06 BRETYLIUM-CONTAINING COMPOSITIONS AND KITS AND THE USE THEREOF FOR PREVENTING AND TREATING CARDIOVASCULAR DISEASES
IL144199A IL144199A (en) 1999-01-08 2001-07-08 Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11514399P 1999-01-08 1999-01-08
US60/115,143 1999-01-08
US11656799P 1999-01-21 1999-01-21
US60/116,567 1999-01-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/869,940 Continuation-In-Part US6482811B1 (en) 1999-01-08 2000-01-06 Bretylium compositions and kits, and their use in preventing and treating cardio-vascular conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/271,044 A-371-Of-International US6884792B2 (en) 1999-01-08 2002-10-15 Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions

Publications (2)

Publication Number Publication Date
WO2000040232A2 WO2000040232A2 (en) 2000-07-13
WO2000040232A3 true WO2000040232A3 (en) 2000-11-23

Family

ID=26812887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/000350 Ceased WO2000040232A2 (en) 1999-01-08 2000-01-06 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions

Country Status (10)

Country Link
US (1) US6482811B1 (en)
EP (1) EP1140054B1 (en)
JP (1) JP4750278B2 (en)
AT (1) ATE290857T1 (en)
AU (1) AU781996B2 (en)
CA (1) CA2358459C (en)
DE (1) DE60018704T2 (en)
IL (2) IL144199A0 (en)
MX (1) MXPA01007024A (en)
WO (1) WO2000040232A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884792B2 (en) * 1999-01-08 2005-04-26 Marvin B. Bacaner Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
CA2615975C (en) * 2005-07-22 2012-11-27 The Procter & Gamble Company Compositions for reducing the incidence of drug induced arrhythmia
JP4750499B2 (en) * 2005-08-01 2011-08-17 日華化学株式会社 Ionic liquid and antibacterial agent and antibacterial fiber using the same
AU2014214824B2 (en) * 2013-02-07 2018-11-22 Research Foundation Of The City University Of New York NSAIDs derivatives and uses thereof
US11020411B2 (en) 2015-09-17 2021-06-01 Ohio State Innovation Foundation Carborane compounds and methods of use thereof
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
WO2021183764A1 (en) * 2020-03-11 2021-09-16 Ohio State Innovation Foundation Methods of modulating t-cell activation using carboranes and carborane analogs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911125A (en) * 1973-05-23 1975-10-07 Marvin B Bacaner Method of treating angina pectoris, coronary insufficiency, and preventing myocardial infarction
WO1987005505A1 (en) * 1986-03-21 1987-09-24 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US5036106A (en) * 1989-09-05 1991-07-30 Bacaner Marvin B Methods for the treatment of disorders of the cardiac vascular system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
US3441649A (en) 1966-08-18 1969-04-29 Univ Minnesota Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate
US4147768A (en) 1976-09-13 1979-04-03 Interx Research Corporation Enteric coated digoxin and therapeutic use thereof
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JP3355593B2 (en) 1994-08-19 2002-12-09 信越化学工業株式会社 Method for producing solid enteric preparation
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
JP3149122B2 (en) 1994-11-07 2001-03-26 信越化学工業株式会社 Base for coating solid enteric preparations
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5980951A (en) 1996-04-10 1999-11-09 Merck & Co., Inc. Oral coated active drugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911125A (en) * 1973-05-23 1975-10-07 Marvin B Bacaner Method of treating angina pectoris, coronary insufficiency, and preventing myocardial infarction
WO1987005505A1 (en) * 1986-03-21 1987-09-24 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US5036106A (en) * 1989-09-05 1991-07-30 Bacaner Marvin B Methods for the treatment of disorders of the cardiac vascular system

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
NEUBERT R. ET AL: "Arzneimitteltransport durch künstliche Lipoidmembran", PHARMAZIE, vol. 42, no. 5, 1987, pages 309 - 311, XP000887145 *
NEUBERT R. ET AL: "Influence of lipophilic counter ions on the transport of ionizable hydrophilic drugs", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 43, no. 3, 1991, pages 204 - 206, XP000886037 *
NEUBERT R. ET AL: "Ion pair approach of bretylium", PHARMAZEUTISCHE INDUSTRIE, vol. 54, no. 4, 1992, pages 370 - 372, XP000886044 *
NEUBERT R.: "In vitro-Modellsysteme zur Beurteilung der Resorption aus dem Gastrointestinal-Trakt - Resorptionsmodelle -", PHARMAZIE, vol. 45, no. 4, 1990, pages 233 - 237, XP000887141 *
NUHN P. ET AL: "Biochemische Grundlagen zur Pharmazeutischen Chemie", PHARMAZIE, vol. 46, no. 1, 1991, pages 61 - 72, XP000887142 *

Also Published As

Publication number Publication date
DE60018704D1 (en) 2005-04-21
AU781996B2 (en) 2005-06-23
MXPA01007024A (en) 2002-03-27
CA2358459C (en) 2011-05-24
ATE290857T1 (en) 2005-04-15
IL144199A0 (en) 2002-05-23
AU2602300A (en) 2000-07-24
JP2002534379A (en) 2002-10-15
JP4750278B2 (en) 2011-08-17
WO2000040232A2 (en) 2000-07-13
EP1140054A2 (en) 2001-10-10
IL144199A (en) 2006-10-05
US6482811B1 (en) 2002-11-19
EP1140054B1 (en) 2005-03-16
CA2358459A1 (en) 2000-07-13
DE60018704T2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2001098236A3 (en) 7-phenyl-substituted tetracycline compounds
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2000006085A3 (en) Compounds and methods
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
WO2000035919A3 (en) Quinoline derivatives
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2004080391A3 (en) Novel antibacterial agents
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
WO2001027118A3 (en) Bicyclic imidazo-5-yl-amine derivatives
EP1319402A4 (en) INHIBITORS OF IgE PRODUCTION
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
WO2001087287A3 (en) Use of pyrazole derivatives for treating infertility
WO2002018954A3 (en) Inhibition of cmv infection and dissemination
WO2001015677A3 (en) Use of 5-ht1b/1d agonists to treat otic pain
WO2002024695A3 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 26023/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2358459

Country of ref document: CA

Ref country code: CA

Ref document number: 2358459

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 144199

Country of ref document: IL

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 591989

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007024

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000904237

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/05931

Country of ref document: ZA

Ref document number: 200105931

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2000904237

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09869940

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2000904237

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 26023/00

Country of ref document: AU